尤瑞克林联合依达拉奉治疗急性脑梗死疗效观察

Observation of curative effect of urinary kallidinogenase combined with edaravone in treatment of acute cerebral infarction

目的探讨尤瑞克林联合依达拉奉治疗急性脑梗死的临床疗效。方法选取在我院干部病房接受治疗的急性脑梗死患者40例,随机分为研究组和对照组各20例。对照组在常规治疗基础上加用依达拉奉治疗,观察组在常规治疗基础上采用尤瑞克林与依达拉奉联合治疗。结果治疗后观察组总有效率95.00%,明显高于对照组(χ2=7.33,P<0.05)。同时观察组的NIHSS评分改善程度明显优于对照组,差异有统计学意义(t=2.93,P<0.05)。结论采用尤瑞克林联合依达拉奉治疗急性脑梗死疗效显著,安全可靠,具有临床推广应用价值。

Objective o investigate the clinical effect of urinary kallidinogenase combined with edaravone in treatment of acute cerebral infarction. Methods Totally 40 cases of the patients with acute cerebral infarction treated in cadre ward in our hospital were randomly divided into study group and control group with 20 cases in each group. The control group was treated on the basis of conventional therapy plus edaravone treatment, the observation group was treated on the basis of the Yurek Lin and edaravone combined therapy. Results After treatment, the total effective rate of observation group was 95%, which was significantly higher than that of the control group （X2= 7.33, P〈0.05）. At the same time, the NIHSS score of the observation group was improved significantly better than that of the control group （t= 2.93, P〈0.05）. Conclusion Urinary kallidinogenase combined with edaravone may have significant curative effects on acute cerebral infarction, and is safe and reliable.